Personalized Nutrition Market (By Product: Active Measurement, Standard Measurement; By Application: Standard Supplement, Disease-based; By End use: Direct-to-consumer, Wellness & Fitness Centers, Hospital & Clinics, Institutions, Food Delivery Services; By Dosage Forms: Tablets, Capsule, Powders, Liquids, Others; By Disease) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022-2030

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Personalized Nutrition Market 

5.1. COVID-19 Landscape: Personalized Nutrition Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Personalized Nutrition Market, By Product

8.1. Personalized Nutrition Market, by Product, 2022-2030

8.1.1. Active Measurement

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Standard Measurement

8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Personalized Nutrition Market, By Application

9.1. Personalized Nutrition Market, by Application, 2022-2030

9.1.1. Standard Supplement

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Disease-based

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Personalized Nutrition Market, By End use 

10.1. Personalized Nutrition Market, by End use, 2022-2030

10.1.1. Direct-to-consumer

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Wellness & Fitness Centers

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Hospital & Clinics

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Institutions

10.1.4.1. Market Revenue and Forecast (2017-2030)

10.1.5. Food Delivery Services

10.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Personalized Nutrition Market, By Dosage Forms

11.1. Personalized Nutrition Market, by Dosage Forms, 2022-2030

11.1.1. Tablets

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Capsule

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Powders

11.1.3.1. Market Revenue and Forecast (2017-2030)

11.1.4. Liquids

11.1.4.1. Market Revenue and Forecast (2017-2030)

11.1.5. Others

11.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Personalized Nutrition Market, By Disease

12.1. Personalized Nutrition Market, by Disease, 2022-2030

12.1.1. Customized to the needs of consumer

12.1.1.1. Market Revenue and Forecast (2017-2030)

12.1.2. Fitness Goal Oriented Application

12.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 13. Global Personalized Nutrition Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Product (2017-2030)

13.1.2. Market Revenue and Forecast, by Application (2017-2030)

13.1.3. Market Revenue and Forecast, by End use (2017-2030)

13.1.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.1.5. Market Revenue and Forecast, by Disease (2017-2030)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.1.6.2. Market Revenue and Forecast, by Application (2017-2030)

13.1.6.3. Market Revenue and Forecast, by End use (2017-2030)

13.1.6.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.1.7. Market Revenue and Forecast, by Disease (2017-2030) 

13.1.8. Rest of North America

13.1.8.1. Market Revenue and Forecast, by Product (2017-2030)

13.1.8.2. Market Revenue and Forecast, by Application (2017-2030)

13.1.8.3. Market Revenue and Forecast, by End use (2017-2030)

13.1.8.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.1.8.5. Market Revenue and Forecast, by Disease (2017-2030)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.2. Market Revenue and Forecast, by Application (2017-2030)

13.2.3. Market Revenue and Forecast, by End use (2017-2030)

13.2.4. Market Revenue and Forecast, by Dosage Forms (2017-2030) 

13.2.5. Market Revenue and Forecast, by Disease (2017-2030) 

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.6.2. Market Revenue and Forecast, by Application (2017-2030)

13.2.6.3. Market Revenue and Forecast, by End use (2017-2030)

13.2.7. Market Revenue and Forecast, by Dosage Forms (2017-2030) 

13.2.8. Market Revenue and Forecast, by Disease (2017-2030) 

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.9.2. Market Revenue and Forecast, by Application (2017-2030)

13.2.9.3. Market Revenue and Forecast, by End use (2017-2030)

13.2.10. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.2.11. Market Revenue and Forecast, by Disease (2017-2030)

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.12.2. Market Revenue and Forecast, by Application (2017-2030)

13.2.12.3. Market Revenue and Forecast, by End use (2017-2030)

13.2.12.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.2.13. Market Revenue and Forecast, by Disease (2017-2030)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Product (2017-2030)

13.2.14.2. Market Revenue and Forecast, by Application (2017-2030)

13.2.14.3. Market Revenue and Forecast, by End use (2017-2030)

13.2.14.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.2.15. Market Revenue and Forecast, by Disease (2017-2030)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.2. Market Revenue and Forecast, by Application (2017-2030)

13.3.3. Market Revenue and Forecast, by End use (2017-2030)

13.3.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.3.5. Market Revenue and Forecast, by Disease (2017-2030)

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.6.2. Market Revenue and Forecast, by Application (2017-2030)

13.3.6.3. Market Revenue and Forecast, by End use (2017-2030)

13.3.6.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.3.7. Market Revenue and Forecast, by Disease (2017-2030)

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.8.2. Market Revenue and Forecast, by Application (2017-2030)

13.3.8.3. Market Revenue and Forecast, by End use (2017-2030)

13.3.8.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.3.9. Market Revenue and Forecast, by Disease (2017-2030)

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.10.2. Market Revenue and Forecast, by Application (2017-2030)

13.3.10.3. Market Revenue and Forecast, by End use (2017-2030)

13.3.10.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.3.10.5. Market Revenue and Forecast, by Disease (2017-2030)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Product (2017-2030)

13.3.11.2. Market Revenue and Forecast, by Application (2017-2030)

13.3.11.3. Market Revenue and Forecast, by End use (2017-2030)

13.3.11.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.3.11.5. Market Revenue and Forecast, by Disease (2017-2030)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.2. Market Revenue and Forecast, by Application (2017-2030)

13.4.3. Market Revenue and Forecast, by End use (2017-2030)

13.4.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.4.5. Market Revenue and Forecast, by Disease (2017-2030)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.6.2. Market Revenue and Forecast, by Application (2017-2030)

13.4.6.3. Market Revenue and Forecast, by End use (2017-2030)

13.4.6.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.4.7. Market Revenue and Forecast, by Disease (2017-2030)

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.8.2. Market Revenue and Forecast, by Application (2017-2030)

13.4.8.3. Market Revenue and Forecast, by End use (2017-2030)

13.4.8.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.4.9. Market Revenue and Forecast, by Disease (2017-2030)

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.10.2. Market Revenue and Forecast, by Application (2017-2030)

13.4.10.3. Market Revenue and Forecast, by End use (2017-2030)

13.4.10.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.4.10.5. Market Revenue and Forecast, by Disease (2017-2030)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Product (2017-2030)

13.4.11.2. Market Revenue and Forecast, by Application (2017-2030)

13.4.11.3. Market Revenue and Forecast, by End use (2017-2030)

13.4.11.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.4.11.5. Market Revenue and Forecast, by Disease (2017-2030)

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Product (2017-2030)

13.5.2. Market Revenue and Forecast, by Application (2017-2030)

13.5.3. Market Revenue and Forecast, by End use (2017-2030)

13.5.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.5.5. Market Revenue and Forecast, by Disease (2017-2030)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Product (2017-2030)

13.5.6.2. Market Revenue and Forecast, by Application (2017-2030)

13.5.6.3. Market Revenue and Forecast, by End use (2017-2030)

13.5.6.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.5.7. Market Revenue and Forecast, by Disease (2017-2030)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Product (2017-2030)

13.5.8.2. Market Revenue and Forecast, by Application (2017-2030)

13.5.8.3. Market Revenue and Forecast, by End use (2017-2030)

13.5.8.4. Market Revenue and Forecast, by Dosage Forms (2017-2030)

13.5.8.5. Market Revenue and Forecast, by Disease (2017-2030)

Chapter 14. Company Profiles

14.1. DNA Fit

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Superior Supplement Manufacturing

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Metagenetics, Inc.

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Asiamerica, Ingredients

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Nutralliance, Inc.

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Mixfix, Inc.

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Barrington Nutritionals

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Balchem Corporation

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Arizona Nutritional Supplements

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Maat Nutritionals

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

PROCEED TO BUY

   USD 4500
   USD 7000
   USD 9000

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client

Get a Sample